FRA:5HB's PB Ratio is ranked better than 93.5% of 1230
companies
in the Biotechnology industry
Industry Median: 2.99
vs FRA:5HB: 0.58
During the past 12 months, Shanghai Haohai Biological Technology Co's average Book Value Per Share Growth Rate was 5.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.80% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Haohai Biological Technology Co was 72.00% per year. The lowest was -3.10% per year. And the median was 6.70% per year.
Back to Basics: PB Ratio
Shanghai Haohai Biological Technology Co (FRA:5HB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Shanghai Haohai Biological Technology Co PB Ratio Related Terms
Shanghai Haohai Biological Technology Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co PB Ratio Chart
Shanghai Haohai Biological Technology Co Annual Data
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co PB Ratio vs Biotechnology Industry
Shanghai Haohai Biological Technology Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a PB Ratio of 0.57 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 45% below median its historical median of 1.04. Over the past decade, Shanghai Haohai Biological Technology Co's PB Ratio has ranged from 0.56 to 1.44. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 1230 companies in the Biotechnology industry, placing it in the top 6.5%.
Is Shanghai Haohai Biological Technology Co's PB Ratio too high?
Shanghai Haohai Biological Technology Co's current PB Ratio of 0.57 is 45% below median its 10-year median of 1.04. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.44. The Biotechnology industry median PB Ratio is 2.99. Shanghai Haohai Biological Technology Co's value of 0.57 is 80.9% below this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 1230 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #80 out of 1230 companies for PB Ratio. This places Shanghai Haohai Biological Technology Co in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.99. Shanghai Haohai Biological Technology Co's value of 0.57 is 80.9% below this benchmark. Historically, Shanghai Haohai Biological Technology Co's own PB Ratio has ranged from 0.56 to 1.44 over the past decade. While the company's 10-year median is 1.04 vs. the industry median of 2.99, Shanghai Haohai Biological Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current PB Ratio of 0.57 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current PB Ratio is 0.57, which is 45% below median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.59, compared to a current price of €1.72 — trading 33.6% below its estimated fair value. The current PB Ratio is 0.57, which is 45% below median its 10-year median of 1.04 and 80.9% below the Biotechnology industry median of 2.99. Shanghai Haohai Biological Technology Co's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current PB Ratio is 0.57 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.72 is trading 33.6% below its estimated GF Value™ of €2.59.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
PB Ratio: 0.57 (45% below median its 10-year median of 1.04)
GF Value™: €2.59 vs. price of €1.72 (33.6% below fair value)
Industry Position: 80.9% below the Biotechnology median (#80 of 1230)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
67GF Score
Get the complete analysis for FRA:5HB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
